Two studies have reported that hepatocyte nuclear factor 4 alpha and bone morphogenetic protein 4 can promote the differentiation of CD133+ HCC stem cells, inhibition of self-renewal, and resistance to chemotherapy[18,19]; and these results suggest that inducing CSC differentiation is a promising approach to the treatment of HCC. This evidence concerns the gene PROM1 and hepatocellular carcinoma.